Background/Aims: The role of ZFX in tumourigenesis is unclear. We aimed to study ZFX expression, regulation, and function and the clinical implications of this protein in human pancreatic cancer (PCa). Methods: One hundred and twenty patients with histologically confirmed PCa who underwent surgery were recruited for this study. Tumour samples and PCa cell lines were used to examine ZFX. Various cell functions related to tumourigenesis were assessed. In vivo mouse tumour xenografts were used to confirm the in vitro results. Results: Patients with ZFX-positive tumours had worse overall survival than patients with ZFX-negative tumours. The depletion of ZFX using lentiviral shRNAs significantly inhibited cell proliferation by inducing cell cycle arrest in G0/G1 phase and resulted in increased cell apoptosis and invasive repression. In vivo studies confirmed that ZFX promoted tumour growth. Mechanistically, MAPK pathway activation was involved in the oncogenic functions of ZFX. Conclusions: ZFX acts as a putative oncogene in PCa and could be a novel therapeutic target for this disease.
Introduction
Pancreatic cancer (PCa) is the most lethal solid tumour and is the fourth leading cause of cancer-related death, with an overall 5-year survival rate of <5% [1, 2] . Due to local invasion, early metastasis, and resistance to standard chemotherapy, the median survival time of PCa patients is only 5-8 months despite recent advances in surgical techniques and medical management [3, 4] . In addition, although surgical resections are commonly performed, the long-term survival of PCa has not improved in two decades [5, 6] . Therefore, identification of effective early markers for the diagnosis and prognosis of the disease as well as novel therapeutic targets will be clinically valuable.
Zinc finger protein X-linked (ZFX), which is encoded on the X chromosome, contains an acidic transcriptional activation domain, a nuclear localization sequence, and a DNA binding domain consisting of 13 C2H2-type zinc fingers [7] . ZFX is highly conserved in vertebrates. Studies have demonstrated that ZFX plays a key role in controlling the self-renewal of embryonic and haematopoietic stem cells [8] . Recently, ZFX was shown to be involved various physiological functions, including proliferation, differentiation, cell cycle and cell death [9, 10] . Consistent with these critical roles, ZFX has been characterized as an oncogene in laryngeal squamous cell carcinoma, hepatocellular carcinoma, gastric carcinoma and colorectal cancer [11] [12] [13] [14] . Clinicopathological analysis showed that high ZFX expression was correlated with poor prognosis in a variety of solid cancers, and increased ZFX expression was identified as an independent prognostic biomarker [11, 14, 15] . However, the biological function and molecular mechanisms of ZFX in PCa are unclear.
The present study aimed to elucidate the role of ZFX in PCa. To this end, we examined ZFX protein expression and localization in PCa tissues and investigated the phenotypic effects and mechanisms of ZFX in PCa.
Materials and Methods

Patients and clinicopathological data
The study was approved by the ethics committee of Xinhua Hospital, and all patients provided informed consent. Cancer tissue specimens were obtained from 120 PCa patients who underwent radical pancreaticoduodenectomy (without prior radiotherapy or chemotherapy) between 2014 and 2016 at the Department of General Surgery, Xinhua Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, China. All diagnoses of PCa and lymph node metastasis were confirmed by histopathological examination, and adjacent control samples were confirmed to be free of tumour cells. All tissue samples were fixed in 4% formalin immediately after removal and embedded in paraffin for immunohistochemical staining.
Immunohistochemical analysis and evaluation of ZFX expression
Immunohistochemical staining was performed using a standard immunoperoxidase staining procedure, and ZFX expression in the benign and malignant specimens was evaluated as described by Li et al [16] . The sections were semi-quantitatively scored according to the extent of immunoreactivity as follows: 0, 0% immunoreactive cells; 1, <5% immunoreactive cells; 2, 5-50% immunoreactive cells; and 3, >50% immunoreactive cells. Additionally, the staining intensity was scored semi-quantitatively as follows: 0, negative; 1, weak; 2, intermediate; and 3, strong. The final immunoreaction score was defined as the sum of both parameters (extension and intensity), and the samples were classified as negative (0), weakly stained (1-2), moderately stained (3), and strongly stained (4-6). For statistical purposes, only moderate and strong final immunoreaction scores were considered positive; the other final scores were considered negative.
Cell culture
The PANC-1 and MIAPaca-2 were purchased from the Shanghai Institutes for Biological Sciences (Shanghai, China). All cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 
Lentivirus-mediated RNA interference
The guiding strand sequence of human small interfering RNA (siRNA) is 5'-GTCGGAAATTGATCCTTGTAA-3'. The negative control siRNA sequence is 5'-TTCTCCGAACGTGTCACGT-3', with no significant sequence similarity to human gene sequences. Short hairpin RNAs (shRNAs) were synthesized and inserted into the pFH1UGW lentivirus vector containing a CMV-driven EGFP reporter gene and an H1 promoter upstream of restriction sites (NheI/PacI). Recombinant lentiviruses expressing ZFX siRNA or control siRNA (Lv-shZFX or Lv-shCon) were produced by co-transfecting HEK293 cells with pVSVG and pCMV⊿R 8.92 using Lipofectamine 2000 (Invitrogen) in accordance with the manufacturer's instructions. The virus was harvested from the culture medium 2 days after transfection, concentrated by centrifugation, and used for subsequent studies. 
Western blot analysis
Total cell lysates were separated on a 10% SDS-PAGE gel and then transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). Membranes were blocked and then probed with primary antibody against ZFX (1:200 dilution, Abcam, Cambridge, UK) and GAPDH (1:5000 dilution, Santa Cruz Biotechnology, Santa Cruz, CA, USA). After the membranes were washed, they were incubated with horseradish peroxidase-conjugated goat anti-mouse IgG (Santa Cruz, CA, USA) and visualised using the enhanced chemiluminescent detection reagent.
Cell proliferation assay
Cell proliferation was assessed with the CCK8 assay following the manufacturer's instructions. In addition, the absorbance at 450 nm was detected using a microplate reader (Bio-Rad, Hercules, CA, USA). A growth curve was prepared according to the absorbance values at 450 nm. The results reflect the average of three replicates under the same conditions.
Colony formation assay
Both non-transfected and transfected PANC-1 and MIAPaca-2 cells (400 cells/well) were seeded in 6-well plates. The culture medium was changed at regular time intervals. After 14 days of culture, adherent cells were washed twice with PBS and fixed with 4% paraformaldehyde for 30 min at room temperature. Colonies were stained with Giemsa solution for 15 min and then washed with water and air-dried. Cell colonies were counted by light microscopy. Experiments were performed in triplicate.
Cell cycle and apoptosis analyses
Forty-eight hours after lv-shRNA transfection, the cells were collected and stained using the FITC Annexin V Apoptosis Detection Kit I (BD Pharmingen, San Diego, CA, USA). Cell cycle analysis was performed after staining with propidium iodide. Both apoptosis and cell cycle distribution were quantified using a flow cytometer. The data presented are representative of at least three different experiments.
In vitro cell migration assay
Cell migration was assessed using 6.5-mm transwell chambers with a pore size of 8 µm (Corning). Transwell upper chambers were pre-coated with 50 µg/chamber of solubilized basement membrane. DMEM/10% FBS was added to the bottom chamber. PCa cells (2.5 ×10 4 per chamber) were seeded in serumcontaining media in the upper well of the transwell chambers and incubated for about 20 h at 37°C and 5% CO 2 . The cells in the lower chamber (below the filter surface) were fixed in 70% ethanol, stained with 0.1 mg/ml crystal violet solution, and counted under a microscope (20× magnification). Five random visual fields were counted for each well, and the average was determined.
Wound healing assay
Cells were cultured for 72 h until confluency after the designated treatments in 6-well plates. Cells were then treated with mitomycin C (10 μg/ml) at 37°C in a 5% (v/v) CO 2 incubator for 1 h to inhibit cell division. Three separate wounds through the cells were made by moving a sterile 200 μl pipet tip perpendicular to the demarcation line. Cells were gently rinsed with PBS and incubated with 2 ml serum-free media. Cells were photographed under a phase contrast microscope at 0 h (control) and 48 h. Each sample was assayed in triplicate.
Tumour xenografts in nude mice
Four-to 6-week-old nu/nu nude mice were purchased from the Shanghai Laboratory Animal Centre of the Chinese Academy of Sciences (Shanghai, China). All mice were housed under specific pathogen-free conditions following the guidelines of the Ethics Committee of Xinhua Hospital, School of Medicine, Shanghai Jiaotong University. For induction of subcutaneous PCa tumours, two groups (Lv-shCon group, and Lv-shZFX group) of PCa cells ( 1×10 6 ) in 0.1 mL serum-free DMEM were implanted subcutaneously into the left flank of the mice (5 mice/group). Tumour growth was monitored every 3 days and measured in 2 dimensions. Tumour volume was calculated using the formula width 2 (mm 2 )×length (mm)/2, where width and length were the shortest and longest diameters, respectively. After approximately 4 weeks, mice were sacrificed, and primary tumours were collected for further immunohistochemical staining and western blot analysis.
Statistical analysis
Statistical analysis was conducted with SPSS software, version 22.0 (SPSS Inc., Chicago, IL, USA). The data are expressed as the mean±S.D. Independent Student's t-tests and χ 2 tests were used to assess the effects of ZFX in the cell lines. The Kaplan-Meier test was used for univariate survival analysis. The Cox proportional hazard model was used for multivariate analysis and for determining the 95% confidence interval. The results were considered to be significant at P<0.05.
Results
ZFX is highly expressed in patients with PCa and correlated with poor prognosis
To determine the potential role of ZFX in PCa progression, we evaluated ZFX expression in PCa and adjacent control tissues by immunohistochemistry (Fig. 1A) . ZFX was primarily located in the nucleus. Approximately 61.7% (74/120) of the PCa cases had positive ZFX staining in the tumour cells. In contrast, only 38.3% (46/120) of the cases had positive staining in the adjacent control tissues (Fig. 1A-1B, P<0 .001). Next, we assessed the correlation between ZFX expression levels and histopathological parameters in patients with PCa. As shown in Table 1 , ZFX overexpression was significantly correlated with TNM stage (P<0.001) and lymph node metastasis (P<0.001) but not with sex, age, histopathological subtypes, tumour size, or tumour location, indicating a potential role of ZFX in promoting aggressive phenotypes in PCa.
The survival information of the 120 PCa patients was obtained through phone calls. Kaplan-Meier survival analysis revealed that lymph node metastasis (P<0.001) and TNM stage (P<0.001) were significantly associated with the average survival time. The average survival time for ZFX-negative patients was significantly higher than that of patients with positive ZFX expression (P<0.001) ( Table 2 , Fig. 1C ). To obtain a more precise estimate of the prognosis, we used the Cox proportional hazards regression model. The results confirmed that ZFX expression, as well as the presence of lymph node metastasis and TNM stage, was negatively correlated with post-operative survival, suggesting that high ZFX expression is a risk factor (Table 3) .
Ectopic expression of ZFX promotes tumourigenic properties of PCa cells
As unlimited growth, invasiveness, and metastasis are hallmarks of malignancy, we explored the role of ZFX in PCa progression. We silenced ZFX expression in PANC-1 and MIAPaca-2 cells, and the knockdown efficiency is shown in Fig. 2A . ZFX knockdown suppressed the growth of PANC-1 and MIAPaca-2 cells as shown by CCK8 assays (Fig. 2B) . Furthermore, colony formation assays demonstrated that ZFX silencing significantly reduced the number of colonies (Fig. 2C) . These results indicated that ZFX promotes cell growth in vitro. Next, Fig.  2D , the tumour volume and weight of ZFX-depleted xenografts were significantly inhibited compared with the negative control group. I m m u n o h i s t o c h e m i c a l analysis indicated that ZFX and Ki67 levels were substantially decreased in ZFX-depleted implanted tumour tissues (Fig. 2E) .
Metastasis is frequently observed in patients with PCa [4] , and therefore, we investigated whether ZFX might be involved in the migration of PANC-1 and MIAPaca-2 cells. In transwell migration assays, ZFX knockdown significantly impaired the migration of PANC-1 and MIAPaca-2 cells (Fig. 2F) . Moreover, migration was also determined by wound healing assays. Knockdown of ZFX in PCa cells moderately decreased the migration rate (Fig. 2G) . These results suggested that ZFX regulated the proliferation, survival and migration of PCa cells in vitro and further explained the aforementioned correlation of ZFX with poor prognosis of PCa patients.
Effects of ZFX silencing on cell cycle progression and apoptosis
To determine the potential mechanism underlying the role of ZFX in PCa cell growth, we assessed the cell cycle profile of the Lv-shCon and Lv-shZFX groups by FACS analysis 48 h after infection. As shown in Fig. 3A , the cell cycle analysis revealed G0/G1 phase arrest in PCa cells (Fig. 3A) after depletion of ZFX, induced cell cycle arrest in the G0/G1 phase. Furthermore, the effect of ZFX knocgkdown on the expression of cell cycle regulators was examined by real-time PCR and western blot analyses. As shown in Fig. 3B-3C , the protein and mRNA levels of CDK2, CDC25A, and cyclin D1 in the Lv-shZFX group were lower than those in the Lv-shCon group. These results indicated that ZFX knockdown induced cell cycle arrest in the G0/G1 phase, possibly by affecting the expression of cell cycle regulators.
To further investigate whether expression of ZFX affects apoptosis in PCa cells, we performed an apoptosis assay by FACS analysis. Transfection of ZFX shRNA resulted in a significant increase in the percentage of apoptotic cells compared with that of the Lv-shCon in both PCa cell lines (Fig. 3D) . Moreover, knockdown of ZFX dramatically increased the expression of Bax and Bad and decreased the expression of Bcl-2 (Fig. 3E) ; these factors play important roles in apoptosis. The above data indicated that ZFX was involved in the regulation of PCa cell apoptosis and cell cycle progression.
ZFX regulates MAPK/ERK signalling in PCa
To elucidate the molecular mechanisms by which ZFX modulates the tumourigenic properties of PCa cells, we investigated the effects of ZFX on cell survival and cell cyclerelated signalling molecules in PCa cells after Lv-shZFX infection. Western blot analysis showed that transfection with Lv-shZFX significantly decreased p-MEK and p-ERK in both PANC-1 and MIAPaca-2 cells but had no effect on p-STAT3 and p-JNK (Fig. 4A) . Encouraged by the above results, we investigated whether targeting MAPK/ERK could attenuate the oncogenic function of ZFX. We treated PCa cells with the ERK inhibitor SCH772984 and found that this compound inhibited ZFX overexpression-induced cell proliferation and invasion (Fig. 4B-4C ). As expected, SCH772984 also promoted the ZFX overexpression-inhibited apoptosis and G0/G1 phase cell accumulation (Fig. 4D-4E) . Moreover, the downstream genes of the MAPK signalling pathway, including Foxo 3 and PPARγ, were upregulated, which also supports activation of the MAPK pathway in PCa cells (Fig. 4A) . Thus, the data indicated that the MAPK/ERK pathway might participate in the oncogenic function of ZFX.
Discussion
PCa remains a lethal malignancy despite the progress made in elucidating its molecular mechanisms [17, 18] . Therefore, identification of novel methods that can effectively inhibit PCa cell growth and metastasis is urgently needed. Targeted therapies have shown promise in achieving these goals [19] [20] [21] . ZFX, also known as ZNF926, is a sex chromosome gene [21] . This protein is a novel member of the Kruppel C2H2-type ZNF protein family and encodes a zinc finger transcription factor that contains 13 C2H2 type ZNF motifs at the carboxyl terminus [22] . ZFX was originally identified as a factor that determines whether an embryo develops as a male or female. Further studies confirmed that ZFX was required for the selfrenewal of haematopoietic and embryonic stem cells and could regulate cell survival [15, 22] . Furthermore, ZFX forms a unique transcription network with Cnot3, Trim28 and c-Myc that is required for self-renewal in embryonic stem cells, suggesting a potential role of ZFX in tumourigenesis [10, 11] . Recent studies have also linked ZFX upregulation to cancer development and progression in various types of cancer. ZFX facilitates the development of experimental basal cell carcinoma and medulloblastoma in mice initiated by deletion of the Hedgehog (Hh) inhibitory receptor Ptch1. These results indicate that ZFX is a common cellintrinsic regulator of diverse Hh-induced tumours and also suggest new therapeutic targets for these malignancies [23] . Furthermore, knocking down ZFX dramatically inhibited the proliferation and metastasis of glioma cells. Based on these findings, ZFX plays an important role in carcinogenesis. However, to date, ZFX has never been linked to PCa.
In the present study, we found for the first time that significantly increased ZFX expression was detected in the vast majority of PCa tissues compared with adjacent control samples. Moreover, increased ZFX protein expression correlated not only with advanced tumour status but also with poor patient survival, suggesting the significance of ZFX in PCa progression. Notably, Cox multivariate analysis indicated that a high nuclear ZFX level was an independent factor for poor prognosis in PCa patients. Thus, ZFX could be a potential therapeutic target in PCa.
Additionally, we found that ZFX may play an important role in PCa cell apoptosis, cell cycle, metastasis and proliferation in vitro and in vivo. Knockdown of ZFX significantly impaired PCa cell growth in vitro and in vivo and increased the number of apoptotic PANC-1 and MIAPaca-2 cells; these results were further confirmed by enhanced expression of Bad and Bax and reduced expression of Bcl-2, key apoptosis-related factors. Notably, progression through the cell cycle depends on the activation of cyclin-dependent kinases (CDKs) and their regulatory subunits, the cyclins. In this study, we observed that ZFX knockdown inhibited PCa cell proliferation by inducing cell cycle arrest in G0/G1 phase while downregulating CDK2, CDC25A, and Cyclin D1. Thus, ZFX may regulate the expression of cell cycle regulators. Additionally, consistent with the results of a previous study [24, 25] , knockdown of ZFX substantially inhibited cell migration and invasion in PCa cells. These properties might contribute to the ZFX-associated aggressive biological behaviours of PCa.
We further elucidated the downstream signalling pathway responsible for ZFX oncogenic function in PCa and found that the ZFX-mediated tumour growth and metastasis could be, at least partly, attributed to the activation of MAPK/ERK signalling, which is critical for the initiation and progression of PCa. The ZFX-induced MAPK/ERK signalling in PANC-1 and MIAPaca-2 cells was confirmed because targeting MAPK/ERK could attenuate the oncogenic function of ZFX and the upregulation of MAPK/ERK target gene expression. However, the direct link between ZFX and the MAPK/ERK pathway should be further investigated in future studies.
In summary, the present study showed that ZFX might be involved in PCa progression and aggressiveness. The classification of patients according to ZFX expression levels provides 
